GSK to acquire cancer drug developer Nuvalent for $10.6 billion
read at STAT ↗DealNeutral
GSK announced an agreement to purchase Nuvalent, a company focused on cancer therapies, in a transaction valued at $10.6 billion.
The acquisition is intended to broaden GSK’s oncology portfolio and accelerate its pipeline of innovative cancer treatments.
The deal adds to a recent spate of large biopharma mergers, underscoring the sector’s ongoing consolidation as companies seek to strengthen their positions in high-growth therapeutic areas.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more”
read at STAT ↗719 words · retrieved Jun 9
comments(0)
5-min edit window · permanent after that